Atlantic Health System

COVID-19 Clinical Research Study Underway at Atlantic Health System, Including Immune Response Study

With a large number of COVID-19 patients in NJ, many are enrolling in dynamic, new COVID Research Program clinical study
4-Jun-2020 5:45 AM EDT, by Atlantic Health System

Newswise — As the world clamors for effective treatments and a vaccine against coronavirus 19 (COVID-19), Atlantic Health System is calling on its expertise and national reputation for conducting leading edge clinical trials in oncology, neuroscience, cardiology and other fields. The COVID Research Program is rapidly enrolling patients from New Jersey, which has one of the world’s highest concentrations of COVID-19 patients. Internationally known academic medical centers from other parts of the country are partnering with Atlantic Health System to increase access to innovative trials. 

“Almost overnight, we have built a robust COVID-19 clinical research study,” said Eric Whitman, MD, medical director, Atlantic Health System Cancer Care. “The caliber of our research program is a result of the hard work and dedication of our physicians, staff, research team, external research partnerships and our reputation,” added Dr. Whitman. 

Atlantic Health System Offers Immune Response Study

Atlantic Health System offers a study sponsored by TScan Therapeutics, Inc., a leading T cell therapeutics company in Waltham, Massachusetts, focused on identifying the precise way the human immune system recognizes and responds to infections like COVID-19 or other diseases, like cancers. TScan has developed a novel technology that enables them to identify the natural targets of T cells.

The purpose of this study is to understand how immune cells mount an immune response to COVID-19. This knowledge will be used in an effort to develop new treatments, vaccines, or diagnostics against COVID-19. Patients who have recently recovered from a COVID-19 infection have immune cells with the ability to recognize and attack the virus, but it is not clear how immune cells recognize COVID-19. TScan is leveraging its proprietary discovery platform to identify the precise epitopes recognized by T cells in COVID-19 recovered patients.

“Recovered patients, who choose to volunteer for the TScan clinical research study, will have a one-time blood sample collected so researchers can study how the patient’s T cells recognize and control the virus,” said Principal Investigator Angela Alistar, MD, medical director of the Breakthrough Treatment Center, and of GI Medical Oncology at Morristown Medical Center. “The goal is to use this information to design effective vaccines that will generate appropriate T cell responses in people who have not yet been infected with the virus.”

This research could be used to generate a vaccine which should provide individuals with robust immunity against any potential future COVID-19 infection.

The COVID Research Program 

Atlantic Center for Research and Atlantic Health System Cancer Care recruited experts in research from the oncology, infectious diseases and research departments at Morristown and Overlook medical centers to form and conduct new studies focused on COVID-19. Once the pandemic hit, the group volunteered to focus on getting a world-class COVID Research Program off the ground. Other departments soon joined in, including cardiac research, cystic fibrosis research and radiation therapy. 

“The COVID Research Team is fast-tracking a broad range of exciting research studies and doing whatever they can to improve the quality of care for patients,” said Jan Schwarz-Miller, MD, MPH, Chief Medical and Academic Officer, Atlantic Health System.

“Our research team has stepped forward, working long hours to make this happen and rapidly enrolling many of the region’s patients in our clinical trials.” 

Among others, the physician investigators include infectious disease specialists, Jason A. Kessler, MD, from Morristown Medical Center, and Robert J. Roland, DO, from Overlook Medical Center; pulmonary and critical care physicians Lewis Rubinson, MD, PhD and Stanley Fiel, MD from Morristown Medical Center; John Halperin, MD, medical director, Atlantic Health System Neuroscience; Elliot Rosenstein, MD, medical director, Institute for Rheumatic and Autoimmune Diseases, Overlook Medical Center; and several members of Atlantic Medical Group Oncology: Charles M Farber, MD, PhD, medical director of Oncology Research Network Development for Atlantic Health System; Mohamad Cherry, MD, medical director of Hematology, Morristown Medical Center; Sophie Morse, MD, oncology, Overlook Medical Center; and Dr. Alistar and Dr. Whitman. 

To learn more about COVID-19 clinical trials at Atlantic Health System, visit www.atlantichealth.org/research.

 

About Atlantic Health System 

Atlantic Health System has a long-standing tradition of providing exceptional patient outcomes and experiences. Home to seven award-winning hospitals including Morristown Medical Center, the number one hospital in NJ according to U.S. News & World Report, Castle Connolly and Newsweek’s World’s Best Hospitals, the system has been ranked first in New Jersey in consumer preference by Monigle and first among health systems in New Jersey as a “best workplace” by both Modern Healthcare and Fortune Magazine. 

Many of the system’s programs have received national accolades and designations, including Morristown Medical Center’s Cardiology and Heart Surgery program ranked among the top 30 in the nation by U.S. News and World Report; Morristown Medical Center’s Orthopedics program ranked among the top 35 in the nation by U.S. News and World Report and Atlantic Health System’s Cancer Care program, New Jersey’s first and only National Cancer Institute National Community Oncology Research Program. Additionally, Atlantic Health System Neuroscience at Overlook Medical Center, working with Atlantic Mobile Health, was the first in the nation to deploy and use portable Telestroke technology in ambulances for routine pre-hospital assessment of stroke patients. 

Powered by a passionate workforce of 17,000 team members and 4,800 affiliated physicians dedicated to building healthier communities, Atlantic Health System serves more than half of the state of New Jersey, including 11 counties and 4.9 million people. The system provides care for the full continuum of health needs across a wide array of settings, including Atlantic Medical Group, one of the largest multi-specialty practices in New Jersey with more than 1,000 physicians and providers, 12 urgent care centers, Atlantic Rehabilitation Institute, Atlantic Home Care and Hospice and Atlantic Anywhere’s Virtual Visits. Facilitating connections between these services on both land and air is the transportation fleet of Atlantic Mobile Health. 

With a clear sense of purpose and an unparalleled culture, Atlantic Health System attracts top leaders in the field of health care, from CEO Brian Gragnolati, who was Chairman of the American Hospital Association in 2019, to the numerous team members who serve as leaders across national clinical associations and research entities.




Filters close

Showing results

110 of 4219
Released: 4-Dec-2020 4:30 PM EST
New review confirms disproportionate impact of COVID-19 on Black, Hispanic populations
Oregon Health & Science University

Black and Hispanic populations are disproportionately affected by COVID-19, according to a systematic review published this week.

Newswise: 250647_web.jpg
Released: 4-Dec-2020 4:05 PM EST
For nationalistic regimes, similar COVID-19 policies are the sincerest form of flattery
University of Texas at Arlington

Analysis from a University of Texas at Arlington assistant professor of public policy suggests that nationalistic governments around the globe are more likely to copy other nationalistic governments in responding to the current pandemic.

Released: 4-Dec-2020 3:15 PM EST
New Study Finds Once Hospitalized, Black Patients with COVID-19 Have Lower Risk of Death than White Patients
NYU Langone Health

A team of investigators at NYU Langone Health has found that once hospitalized, Black patients (after controlling for other serious health conditions and neighborhood income) were less likely to have severe illness, die, or be discharged to hospice compared to White patients.

Released: 4-Dec-2020 2:35 PM EST
AANA Commends CDC on Prioritizing COVID-19 Vaccine Distribution to Healthcare Personnel
American Association of Nurse Anesthetists (AANA)

The American Association of Nurse Anesthetists (AANA) commends the U.S. Centers for Disease Control and Prevention’s (CDC's) team of advisors on prioritizing frontline healthcare personnel and residents of long-term facilities for the first phase of the COVID-19 vaccine distribution.

Released: 4-Dec-2020 1:50 PM EST
COVID-19 in Victorian schools and childcare mainly driven by community transmission
Murdoch Childrens Research Institute

Analysis of Victorian data by the Murdoch Children's Research Institute suggests that COVID-19 cases in schools and childcare were mainly driven by community transmission

Released: 4-Dec-2020 12:20 PM EST
Identifying markers of COVID-19 infection using blood tests
University of Seville

Researchers from the Institute of Biomedicine of Seville (IBIS) have presented a study carried out in the Clinical Biochemistry Service of the Virgen del Rocío University Hospital which identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19).

Released: 4-Dec-2020 12:05 PM EST
Research confirms crucial monitoring assessment is effective for patients with COVID-19
University of Portsmouth

A combined research team from the Universities of Portsmouth and Bournemouth and Portsmouth Hospitals University NHS Trust has shown that an assessment score used to measure a patient's severity of illness can be applied to patients with Covid-19 without modification.

Newswise:Video Embedded flccc-alliance-calls-on-national-health-authorities-to-immediately-review-medical-evidence-showing-the-efficacy-of-ivermectin-for-the-prevention-of-covid-19-and-as-an-early-outpatient-treatment
VIDEO
Released: 4-Dec-2020 12:00 PM EST
FLCCC Alliance Calls on National Health Authorities to Immediately Review Medical Evidence Showing the Efficacy of Ivermectin for the Prevention of COVID-19 and as an Early Outpatient Treatment
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

“Following the swi. review— and subsequent guidance— by the NIH and theCDC of Ivermectin, we expect that Ivermectin’s widespread, immediate use willallow for a rapid and safe re-opening of businesses and schools across the nation—and quickly reduce the strain on overwhelmed ICUs.” —FLCCC Alliance

Released: 4-Dec-2020 11:50 AM EST
Immunity passports: Ethical conflict and opportunity
University of the Basque Country

Immunity passports are a means of registering whether an individual has developed immunity to COVID-19 and is therefore unlikely to either catch or spread the disease.


Showing results

110 of 4219

close
1.90654